- Trials with a EudraCT protocol (95)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (19)
95 result(s) found for: interferon gamma.
Displaying page 4 of 5.
EudraCT Number: 2022-001316-26 | Sponsor Protocol Number: APHP200007 | Start Date*: 2022-09-12 | |||||||||||
Sponsor Name:Assistance Publique Hôpitaux de Paris / DRCI | |||||||||||||
Full Title: Multicenter, randomized, prospective trial comparing the Efficacy and Safety of Adalimumab to that of Tocilizumab in severe uveitis of Behçet’s disease UVB Study | |||||||||||||
Medical condition: severe uveitis of Behçet’s disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003753-13 | Sponsor Protocol Number: P160909 | Start Date*: 2019-03-19 |
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS | ||
Full Title: Multicentre, randomized, prospective trial comparing the efficacy and safety of Infliximab to tocilizumab in refractory or relapsing Takayasu arteritis | ||
Medical condition: Patients with refractory or relapsing Takayasu Arteritis desease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2018-003653-16 | Sponsor Protocol Number: S62092 | Start Date*: 2019-03-21 | |||||||||||
Sponsor Name:UZ Leuven | |||||||||||||
Full Title: Abatacept in patients with Birdshot HLA A29 uveitis: A Phase II Prospective 0pen Label Interventional Proof-of-Concept Study | |||||||||||||
Medical condition: Birdshot Uveitis HLA A29 retinochoroiditis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005036-26 | Sponsor Protocol Number: FXT-05 | Start Date*: 2011-11-29 | ||||||||||||||||||||||||||
Sponsor Name:Funxional Therapeutics Ltd | ||||||||||||||||||||||||||||
Full Title: An Exploratory Phase IIa Study to Investigate the Biological Activity of Oral FX125L in Adult Patients with Chronic Inflammatory Disease | ||||||||||||||||||||||||||||
Medical condition: Asthma Chronic obstructive pulmonary disease Rheumatoid arthritis Psoriasis | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011121-13 | Sponsor Protocol Number: TG4040.02 | Start Date*: 2010-07-27 | |||||||||||
Sponsor Name:TRANSGENE S.A. | |||||||||||||
Full Title: A phase II randomized, multicenter, open-label study of TG4040 (MVA-HCV) in combination with pegylated interferon alfa-2a and ribavirin versus pegylated interferon alfa-2a and ribavirin in treatmen... | |||||||||||||
Medical condition: Treatment of patients with chronic genotype 1 hepatitis C | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002279-16 | Sponsor Protocol Number: EOGBM1-18 | Start Date*: 2020-01-02 | |||||||||||
Sponsor Name:Enterome | |||||||||||||
Full Title: A MulticenteR, Open-Label, First-in-Human, PhaSe Ib/IIa Trial of EO2401, a Novel Multipeptide Therapeutic VAccine, with and without PD-1 Check Point Inhibitor, FoLlowing Standard Treatment in PatIe... | |||||||||||||
Medical condition: Progressive or recurrent Glioblastoma (PG) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003303-35 | Sponsor Protocol Number: IB2019-04 | Start Date*: 2021-04-08 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Institut Bergonié | ||||||||||||||||||||||||||||||||||||||
Full Title: Combining epigenetic and immune therapy to beat cancer | ||||||||||||||||||||||||||||||||||||||
Medical condition: | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004793-26 | Sponsor Protocol Number: HPN217-3001 | Start Date*: 2020-06-24 | |||||||||||
Sponsor Name:Harpoon Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients with Relapsed/Refractory Multiple Myeloma | |||||||||||||
Medical condition: Relapsed/Refractory Multiple Myeloma (RRMM) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001314-42 | Sponsor Protocol Number: IM103116 | Start Date*: 2013-09-11 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: Evaluation of the Benefits and Risks in Maintenance Renal Transplant Recipients Following Conversion to Nulojix® (belatacept)-based Immunosuppression | |||||||||||||
Medical condition: Maintenance of renal transplant recipients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) AT (Completed) DE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003255-54 | Sponsor Protocol Number: RGB-03-104 | Start Date*: 2015-01-21 | |||||||||||
Sponsor Name:Gedeon Richter Plc | |||||||||||||
Full Title: A Double-blind, Randomised, Comparative Pharmacokinetic, Pharmacodynamic, Efficacy and Safety Evaluation of RGB-03 and MabThera® Combined with Methotrexate in Rheumatoid Arthritis Patients | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004444-29 | Sponsor Protocol Number: RID-TB:Treat | Start Date*: 2020-11-25 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: An open-label, multi-centre, randomised controlled trial evaluating the effects of short-course rifapentine-based regimens and additional adherence support on LTBI treatment adherence and completio... | |||||||||||||
Medical condition: Latent Tuberculosis infection (LTBI) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002264-41 | Sponsor Protocol Number: P160932J | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Etude randomisée multicentrique évaluant l’efficacité et la tolérance de l’infliximab comparativement au Cyclophosphamide dans les formes sévères de maladie de Behçet " Multicenter, randomized, pro... | |||||||||||||
Medical condition: Induction Therapy with Anti-TNF vs Cyclophosphamide in severe Behçet disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001968-78 | Sponsor Protocol Number: ADC4022_CLIN_02P | Start Date*: 2007-07-20 | |||||||||||
Sponsor Name:Argenta Discovery Ltd. | |||||||||||||
Full Title: A Phase II, Randomised, Double-Blind, Placebo-Controlled Pilot Efficacy Study of ADC4022 (Theophylline Solution for Inhalation) on Markers of Pulmonary Inflammation in Subjects with Moderate to Sev... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-004558-44 | Sponsor Protocol Number: 2021-00604 | Start Date*: 2021-10-10 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:UMCG | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Optimal Booster Strategy for SARS-CoV-2 Vaccination in Kidney Transplant patients | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: COVID-19 is associated with severely increased morbidity and mortality in kidney transplant patients. Available data show that the immune response after a standard regimen of two mRNA vaccinations ... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-003811-23 | Sponsor Protocol Number: IMG-7289-CTP-102 | Start Date*: 2019-12-11 | |||||||||||||||||||||
Sponsor Name:Imago BioSciences, Inc. | |||||||||||||||||||||||
Full Title: A Multi-Center, Open Label Study to Assess the Safety, Steady State Pharmacokinetics and Pharmacodynamics of IMG-7289 in Patients with Myelofibrosis | |||||||||||||||||||||||
Medical condition: Myelofibrosis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) IT (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-001778-17 | Sponsor Protocol Number: 201190 | Start Date*: 2016-03-17 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
Full Title: A phase IIIb, open-label, multi-country, multi-centre, long-term follow-up study (ZOE-LTFU) of studies 110390 and 113077 (ZOSTER-006/022) to assess the prophylactic efficacy, safety, and immunogeni... | |||||||||||||
Medical condition: Vaccination against HZ and its related complications in adults older than 50 years (at the time of primary vaccination). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) EE (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) DE (Completed) ES (Ongoing) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000880-34 | Sponsor Protocol Number: 207489 | Start Date*: 2017-10-10 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
Full Title: A Phase IIB, randomised, observer-blind, placebo-controlled, multi-centre study to evaluate the efficacy, safety, reactogenicity and immunogenicity of the GSK Biologicals’ investigational vaccine G... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) ES (Completed) DE (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003396-19 | Sponsor Protocol Number: EOADR1-19 | Start Date*: 2020-05-28 | |||||||||||||||||||||
Sponsor Name:Enterome | |||||||||||||||||||||||
Full Title: A phase 1/2 trial of EO2401, a novel microbial-derived peptide therapeutic vaccine, in combination with PD-1 check point blockade, for treatment of patients with locally advanced or metastatic adr... | |||||||||||||||||||||||
Medical condition: - locally advanced or metastatic adrenocortical carcinoma (ACC) - malignant pheochromocytoma/paraganglioma (MPP) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Completed) NL (Ongoing) ES (Completed) DE (Completed) DK (Completed) IT (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001191-38 | Sponsor Protocol Number: CRAD001HES01 | Start Date*: 2013-08-21 |
Sponsor Name:Novartis Farmacéutica, S.A. | ||
Full Title: Multicentric, randomized, open-label, controlled study, of 12 months of follow-up to assess the effect in renal function of a immunosuppressive treatment based on tacrolimus minimization in combin... | ||
Medical condition: Asumiendo una mayor eficacia en la prevención del rechazo agudo en el brazo de everolimus con minimización de los niveles de tacrolimus, la hipótesis del presente ensayo es que la introducción de e... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-005671-14 | Sponsor Protocol Number: 116760 | Start Date*: 2013-09-30 | ||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||
Full Title: A phase III, randomised, open-label, multicentre clinical trial to assess the safety and immunogenicity of GSK Biologicals’ HZ/su candidate vaccine when administered subcutaneously as compared to i... | ||||||||||||||||||
Medical condition: Healthy volunteers (Prevention of Herpes Zoster [HZ] and related complications in adults ≥50 years of age [YOA] and immunocompromised adults ≥18 YOA) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
